European Heart Journal

(The median citation count of European Heart Journal is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure6062
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)5554
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation2912
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2773
2021 ESC/EACTS Guidelines for the management of valvular heart disease2383
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension1263
2020 ESC Guidelines for the management of adult congenital heart disease1020
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy943
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death932
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio869
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease858
COVID-19 is, in the end, an endothelial disease696
2023 ESC Guidelines for the management of acute coronary syndromes616
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe554
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases517
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcircula423
European Society of Cardiology: cardiovascular disease statistics 2021419
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis408
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research373
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement373
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery370
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure365
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study355
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather350
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus341
2023 ESC Guidelines for the management of cardiomyopathies339
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force290
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance276
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine274
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial273
C-reactive protein and clinical outcomes in patients with COVID-19262
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation250
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement238
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions233
2023 ESC Guidelines for the management of endocarditis229
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes212
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study205
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study198
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o197
Left bundle branch area pacing outcomes: the multicentre European MELOS study193
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyc190
Prevalence of statin intolerance: a meta-analysis188
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)184
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials177
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement173
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies172
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study166
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy166
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)164
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes158
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction158
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists147
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)145
Heart failure drug treatment: the fantastic four144
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis142
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults140
The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020136
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies136
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank134
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism133
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials132
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery131
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank130
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction130
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial130
Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study129
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF127
Empagliflozin in acute myocardial infarction: the EMMY trial126
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial126
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)125
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes124
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial123
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study122
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial120
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme120
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial117
Application of artificial intelligence to the electrocardiogram116
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk116
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis115
Electrocardiogram screening for aortic valve stenosis using artificial intelligence112
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry104
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake103
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial101
Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study101
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up99
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS98
Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial98
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study98
Combination lipid-lowering therapy as first-line strategy in very high-risk patients97
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial96
Colchicine and the heart95
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation95
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a s94
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)93
Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk93
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk91
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study90
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality89
Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease89
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome89
Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy89
Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry88
Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)88
Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction88
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial88
Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group88
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations88
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials88
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials87
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with th86
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial86
Frailty and cardiovascular outcomes in the National Health and Aging Trends Study86
Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes85
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial85
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis85
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial85
The win ratio approach for composite endpoints: practical guidance based on previous experience84
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy83
The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EA83
Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation83
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy82
Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study82
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial82
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percuta81
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombo81
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure81
Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry80
Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis80
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction80
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial79
Assessment and pathophysiology of microvascular disease: recent progress and clinical implications78
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study78
A practical risk score for early prediction of neurological outcome after out-of-hospital cardiac arrest: MIRACLE278
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial78
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis78
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme78
Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction77
The “ten commandments” for the 2021 ESC/EACTS Guidelines on valvular heart disease76
Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models76
Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up76
Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the E76
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis76
Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial76
Sex differences in arterial hypertension75
The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction74
Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data74
Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance73
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the He73
A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study73
The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms72
Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy72
Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial72
Targeting the CCL2–CCR2 axis for atheroprotection72
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study72
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance71
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis71
Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection71
Feasibility of using deep learning to detect coronary artery disease based on facial photo71
The ‘10 commandments’ for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy70
Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study70
Road traffic noise and cardiovascular disease risk factors in UK Biobank69
Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole69
Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translat69
Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention69
Stress-associated neurobiological activity associates with the risk for and timing of subsequent Takotsubo syndrome68
Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data68
Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death67
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis67
STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases66
High-density lipoprotein revisited: biological functions and clinical relevance66
Assessing left ventricular systolic function: from ejection fraction to strain analysis66
Outdoor light at night and risk of coronary heart disease among older adults: a prospective cohort study66
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score66
Metoprolol exerts a non-class effect against ischaemia–reperfusion injury by abrogating exacerbated inflammation66
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality65
Heart healthy cities: genetics loads the gun but the environment pulls the trigger64
Critical appraisal of artificial intelligence-based prediction models for cardiovascular disease64
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences64
Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease63
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease63
Effects of canagliflozin on human myocardial redox signalling: clinical implications63
Acute mental stress drives vascular inflammation and promotes plaque destabilization in mouse atherosclerosis63
The dawn of a new era of targeted lipid-lowering therapies63
Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study63
Mendelian randomization for cardiovascular diseases: principles and applications63
Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial62
Brugada syndrome genetics is associated with phenotype severity62
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR62
The struggle towards a Universal Definition of Heart Failure—how to proceed?61
Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank61
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial60
Targeted proteomics improves cardiovascular risk prediction in secondary prevention60
Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis60
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study59
Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (A59
A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs59
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe59
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications59
Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction58
Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?58
Association of the combined effects of air pollution and changes in physical activity with cardiovascular disease in young adults57
Iron deficiency and cardiovascular disease57
Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry57
Restrictive cardiomyopathy: definition and diagnosis56
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary s56
Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled56
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey56
Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality55
Sleep arousal burden is associated with long-term all-cause and cardiovascular mortality in 8001 community-dwelling older men and women55
PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction55
Vigorous physical activity, incident heart disease, and cancer: how little is enough?55
Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome54
Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR454
Extracellular vesicles from immortalized cardiosphere-derived cells attenuate arrhythmogenic cardiomyopathy in desmoglein-2 mutant mice54
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis54
Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial54
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventio54
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study53
Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry53
Silent brain infarcts impact on cognitive function in atrial fibrillation53
Prognostic value of stress echocardiography assessed by the ABCDE protocol53
Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy52
Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study52
Artificial intelligence in the diagnosis and management of arrhythmias52
A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study51
Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.2351
Dapagliflozin for heart failure according to body mass index: the DELIVER trial51
Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective51
Tilt testing remains a valuable asset51
Automated external defibrillators delivered by drones to patients with suspected out-of-hospital cardiac arrest51
Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA51
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox51
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy50
Smoking cessation, but not reduction, reduces cardiovascular disease incidence50
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study50
Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock50
Accelerated and personalized therapy for heart failure with reduced ejection fraction50
Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms50
Trends in survival after cardiac arrest: a Swedish nationwide study over 30 years50
Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study50
Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis49
SGLT2 inhibitors: the statins of the 21st century49
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials49
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score49
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia49
All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study49
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm48
A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity48
Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification47
Ventricular arrhythmia burden during the coronavirus disease 2019 (COVID-19) pandemic47